Jazz Pharmaceuticals has sold a priority review voucher (PRV) for $200m, suggesting the uptick in market prices for the regulatory fast-track ticket seen over recent years shows no signs of slowing.

Even in the era of the FDA's Commissioner's National Priority Voucher (CNPV) program, Jazz Pharmaceuticals is showing that traditional priority review vouchers (PRVs) can catch a pretty penny. In fact ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Telephone & Data Systems, Inc. is a diversified telecommunications company, which engages in the provision of communications services, retail wireless connections, broadband, video, and voice ...

The US rare disease specialist ended Q3 2025 with over $2bn in cash and investments. Credit: Piotr Swat via Shutterstock.com. Jazz Pharmaceuticals has sold a priority review voucher (PRV) for $200m, ...

Recently, the US Senate committee blocked a bipartisan bill to reintroduce the US Food and Drug Administration’s (FDA) Priority Review Voucher (PRV) scheme; a program designed to prioritize review and ...

Half of the net proceeds will go to Jazz; it remains unclear who will get the remaining sum. Jazz did not reveal the buyer of the voucher. Jazz Pharmaceuticals has offloaded a priority review voucher ...

Abstract: The recent global urbanization problem has set the industry and researchers sights to the importance of safe, effective water distribution due to the unprecedent demand placed on our aging ...